MYnd Analytics adds genomics to PEER Report, Building a “Gold-Standard” for evidence-based prescribing
MISSION VIEJO, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:CNSO) has reached agreements with national laboratories to add genetic testing to its PEER Report. This combination offers physicians and patients a unique opportunity to use objective brain and metabolic measures to guide treatment.
The PEER Report is generated from an individual’s EEG recording, a measure of brain function, which is then analyzed against MYnd’s patented database of over 10,000 individual patients to produce the report, which can help physicians reduce trial and error prescribing.
Similarly, the genetic panel is a simple cheek swab which can be used to predict how an individual will metabolize medications. Certain gene variations are known to limit medication effectiveness or produce unexpected side effects. This supplemental information will aid physicians and patients in selecting the most appropriate treatment for mental health disorders.
“Physicians using the objective data provided in the PEER Report have been able to more effectively prescribe appropriate medications, and adding complementary genetic information will help physicians understand a patient’s ability to metabolize those medications. This combination of brain and metabolic information will enable the physician to make even more informed decisions and improve patient outcomes,” said George Carpenter, CEO of MYnd Analytics.
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Media Contact: Lauren Jenkins ScoutComms (202) 596-5669
Released May 26, 2016